TRC 150094

Drug Profile

TRC 150094

Alternative Names: TRC150094

Latest Information Update: 07 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Torrent Pharmaceuticals
  • Class Obesity therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias
  • No development reported Metabolic syndrome

Most Recent Events

  • 22 Aug 2017 Torrent Pharmaceuticals plans a phase III trial for Diabetes, Dyslipidaemias and Hypertension (NCT03254446)
  • 23 Sep 2015 No recent reports on development identified - Phase-I/II for Metabolic syndrome in India and the Netherlands (PO)
  • 16 Apr 2013 Torrent Pharmaceuticals plans a phase II trial for Dyslipidaemia in India (CTRI2013-03-003444)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top